Department of Vascular Intervention, Jingmen People's Hospital, Jingmen, Hubei, China.
Interventional Department, Qujing Second People's Hospital, Qujing, Yunnan, China.
Front Immunol. 2024 Oct 22;15:1422784. doi: 10.3389/fimmu.2024.1422784. eCollection 2024.
The purpose of this study was to compare the safety and efficacy of drug-eluting bead (DEB) transarterial chemoembolization combined with lenvatinib and camrelizumab (DEB-TACE-Len-C) and DEB-TACE-Len for the treatment of unresectable hepatocellular carcinoma (uHCC).
This retrospective study consecutively included uHCC patients who underwent DEB-TACE-Len-C or DEB-TACE-Len treatment at our hospital and Qujing Second People's Hospital from April 2020 to April 2022. In total, 85 patients were enrolled. There were 42 patients in the DEB-TACE-Len-C group and 43 patients in the DEB-TACE-Len group. The disease control rate (DCR), objective response rate (ORR), overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were compared between the two groups, and the factors influencing OS and PFS were analysed.
The ORR, DCR, PFS and OS were significantly greater in the DEB-TACE-Len-C group than in the DEB-TACE-Len group (ORR: 76.2% vs. 46.5%, = 0.005; DCR: 88.1% vs. 67.8%, = 0.039; PFS: 10 months vs. 6 months, 0.0001; OS: 24 months vs. 16 months, = 0.0038). Multivariate Cox proportional hazard regression analysis revealed that portal tumour thrombus (PVTT) and therapeutic approach were independent factors affecting PFS and OS. There were no statistically significant differences in the incidence of AEs between the two groups ( > 0.05).
Compared with DEB-TACE-Len, DEB-TACE-Len-C is an effective treatment option that can improve the tumour therapeutic response and prolong the OS and PFS in uHCC patients.
本研究旨在比较载药微球（DEB）经动脉化疗栓塞（TACE）联合仑伐替尼和卡瑞利珠单抗（DEB-TACE-Len-C）与 DEB-TACE-Len 治疗不可切除肝细胞癌（uHCC）的安全性和有效性。
本回顾性研究连续纳入 2020 年 4 月至 2022 年 4 月期间在我院和曲靖市第二人民医院接受 DEB-TACE-Len-C 或 DEB-TACE-Len 治疗的 uHCC 患者。共纳入 85 例患者，DEB-TACE-Len-C 组 42 例，DEB-TACE-Len 组 43 例。比较两组疾病控制率（DCR）、客观缓解率（ORR）、总生存期（OS）、无进展生存期（PFS）和不良反应（AEs），并分析影响 OS 和 PFS 的因素。
DEB-TACE-Len-C 组的 ORR、DCR、PFS 和 OS 均显著高于 DEB-TACE-Len 组（ORR：76.2% vs. 46.5%， = 0.005；DCR：88.1% vs. 67.8%， = 0.039；PFS：10 个月 vs. 6 个月， 0.0001；OS：24 个月 vs. 16 个月， = 0.0038）。多因素 Cox 比例风险回归分析显示，门静脉癌栓（PVTT）和治疗方法是影响 PFS 和 OS 的独立因素。两组 AEs 发生率无统计学差异（ > 0.05）。
与 DEB-TACE-Len 相比，DEB-TACE-Len-C 是一种有效的治疗选择，可提高 uHCC 患者的肿瘤治疗反应，并延长 OS 和 PFS。
